Ionis Pharmaceuticals (LTS:0JDI) Cyclically Adjusted Book per Share: $5.45 (As of Mar. 2026)


LTS:0JDI Ionis Pharmaceuticals Inc LTS:0JDI
66 GF Score
Price $80.25
GF Value $52.91
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Cyclically Adjusted Book per Share?

Ionis Pharmaceuticals LTS:0JDI +2.50% 66 Cyclically Adjusted Book per Share is $5.45 as of Mar. 2026. GuruFocus rates LTS:0JDI with a GF Score™ of 66/100 and a GF Value™ of $52.91 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Ionis Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was $2.962. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $5.45 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ionis Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 5.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 2.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 5.40% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 12.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Ionis Pharmaceuticals was 20.90% per year. The lowest was -21.40% per year. And the median was 7.05% per year.

As of today (2026-07-03), Ionis Pharmaceuticals's current stock price is $80.25. Ionis Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $5.45. Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 14.72.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ionis Pharmaceuticals was 29.73. The lowest was 5.22. And the median was 13.44.


Ionis Pharmaceuticals  (LTS:0JDI) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=80.25/5.45
=14.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ionis Pharmaceuticals was 29.73. The lowest was 5.22. And the median was 13.44.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Ionis Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Ionis Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Cyclically Adjusted Book per Share Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.71 4.87 5.00 5.12 5.34

Ionis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.14 5.27 5.24 5.34 5.45

LTS:0JDI vs EXEL, BBIO, AXSM: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


LTS:0JDI
66GF Score
Ionis Pharmaceuticals Inc LTS:0JDI
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ionis Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.962/330.2130*330.2130
=2.962

Current CPI (Mar. 2026) = 330.2130.

Ionis Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.920 241.018 1.260
201609 1.153 241.428 1.577
201612 0.819 241.432 1.120
201703 1.629 243.801 2.206
201706 1.736 244.955 2.340
201709 2.471 246.819 3.306
201712 2.249 246.524 3.012
201803 2.402 249.554 3.178
201806 5.076 251.989 6.652
201809 5.167 252.439 6.759
201812 7.599 251.233 9.988
201903 8.649 254.202 11.235
201906 9.042 256.143 11.657
201909 9.502 256.759 12.220
201912 10.482 256.974 13.469
202003 9.766 258.115 12.494
202006 9.873 257.797 12.646
202009 9.894 260.280 12.552
202012 5.295 260.474 6.713
202103 4.829 264.877 6.020
202106 4.132 271.696 5.022
202109 3.758 274.310 4.524
202112 5.465 278.802 6.473
202203 5.006 287.504 5.750
202206 4.405 296.311 4.909
202209 4.185 296.808 4.656
202212 4.033 296.797 4.487
202303 3.402 301.836 3.722
202306 2.992 305.109 3.238
202309 2.200 307.789 2.360
202312 2.679 306.746 2.884
202403 2.033 312.332 2.149
202406 1.806 314.175 1.898
202409 4.198 315.301 4.397
202412 3.726 315.605 3.898
202503 2.991 319.799 3.088
202506 3.968 322.561 4.062
202509 3.835 324.800 3.899
202512 2.995 324.054 3.052
202603 2.962 330.213 2.962

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $5.45 mean?
Ionis Pharmaceuticals (LTS:0JDI) has a Cyclically Adjusted Book per Share of $5.45 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Ionis Pharmaceuticals' current Cyclically Adjusted Book per Share is $5.45. Overall, Ionis Pharmaceuticals has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Cyclically Adjusted Book per Share compare to EXEL and BBIO?
Ionis Pharmaceuticals' Cyclically Adjusted Book per Share of $5.45 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Cyclically Adjusted Book per Share is $5.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (LTS:0JDI) is currently considered Significantly Overvalued. The stock's GF Value™ is $52.91, compared to a current price of $80.25 — trading 51.7% above its estimated fair value. The current Cyclically Adjusted Book per Share is $5.45. Ionis Pharmaceuticals' overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Ionis Pharmaceuticals (LTS:0JDI), the current Cyclically Adjusted Book per Share is $5.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (LTS:0JDI) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of $80.25 is trading 51.7% above its estimated GF Value™ of $52.91. GuruFocus considers Ionis Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for LTS:0JDI:

  • Cyclically Adjusted Book per Share: $5.45
  • GF Value™: $52.91 vs. price of $80.25 (51.7% above fair value)
  • GF Score™: 66/100 with 8 warning signs

No single metric tells the full story. See the LTS:0JDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
66GF Score

Get the complete analysis for LTS:0JDI

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$80.25
Price
$52.91
GF Value